Gutkowicz-Krusin Dina, Rabinovitz Harold S
Electro-Optical Sciences Inc, Irvington, NY 10533, USA.
Melanoma Res. 2007 Dec;17(6):354-9. doi: 10.1097/CMR.0b013e3282f120bf.
A kinetic model for progression of a population of cutaneous melanomas through categories defined by the range of Breslow thickness, with melanomas in situ (MIS) in category 0, and melanomas with Breslow thickness > or =2 mm in category 3, is described. The model assumes that all melanomas start out in category 0; this category is further subdivided into indolent and progressing melanomas. Steady-state solutions for the distributions of excised melanomas were found. Depending on the proportion of indolent MIS, these solutions predict very different distributions of excised melanomas and melanoma mortality, when either frequency of examinations by physicians or sensitivity to melanoma is changed. Although it is not currently possible to differentiate between indolent and progressing MIS either clinically or histologically, solutions of this kinetic model can be used to determine the proportion of such indolent lesions in a population-based study. The steady-state solutions of the kinetic model can be used to analyze melanoma progression in any stable patient population, in which the total number of melanomas detected per year is either stable or varies slowly. As an example, melanoma progression is analyzed using the American Cancer Society estimates of melanoma incidence and mortality. For a fixed incidence rate, melanoma mortality and melanoma treatment cost in the USA could be significantly reduced by increasing the biopsy sensitivity of physicians to in-situ and thin-invasive melanomas.
描述了一种关于皮肤黑色素瘤群体通过由Breslow厚度范围定义的类别进展的动力学模型,原位黑色素瘤(MIS)在0类,Breslow厚度大于或等于2mm的黑色素瘤在3类。该模型假设所有黑色素瘤都起始于0类;该类别进一步细分为惰性和进展性黑色素瘤。找到了切除黑色素瘤分布的稳态解。根据惰性MIS的比例,当医生检查频率或对黑色素瘤的敏感性改变时,这些解预测切除黑色素瘤的分布和黑色素瘤死亡率非常不同。虽然目前在临床或组织学上都无法区分惰性和进展性MIS,但这种动力学模型的解可用于在基于人群的研究中确定此类惰性病变的比例。动力学模型的稳态解可用于分析任何稳定患者群体中的黑色素瘤进展,其中每年检测到的黑色素瘤总数要么稳定要么缓慢变化。例如,使用美国癌症协会对黑色素瘤发病率和死亡率的估计来分析黑色素瘤进展。对于固定的发病率,通过提高医生对原位和薄浸润性黑色素瘤的活检敏感性,美国的黑色素瘤死亡率和黑色素瘤治疗成本可能会显著降低。